This was the stock's second consecutive day of losses.

Inovio Pharmaceuticals (INO) shares rallied 19% in the last trading session to close at $11.04. This move can be attributable to notable volume with a higher number of shares being traded than in ...

Shares of Inovio Pharmaceuticals pulled back by 5.3% during Wednesday's session. The decline may be attributed to profit-taking, as investors assess renewed focus on respiratory illnesses. Inovio ...

Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting ...

TORONTO, January 30, 2025--Inovalis Real Estate Investment Trust (the "REIT") (TSX: INO.UN) announced its first LEED Platinum certification for the Francisca Delgado 9 building, located in ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Free Report ... has a “Neutral” rating and a $3.00 target price on the stock. The consensus estimate for Inovio Pharmaceuticals’ current ...

They currently have a neutral rating on the biopharmaceutical company’s stock. Several other analysts have also recently weighed in on INO. Oppenheimer dropped their price objective on Inovio ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...

Shares of Inovio Pharmaceuticals Inc. INO slipped 1.96% to $2.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising ...